306 related articles for article (PubMed ID: 16248766)
1. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
Rogers BE; Roberson PL; Shen S; Khazaeli MB; Carpenter M; Yokoyama S; Brechbiel MW; LoBuglio AF; Buchsbaum DJ
Cancer Biother Radiopharm; 2005 Oct; 20(5):502-13. PubMed ID: 16248766
[TBL] [Abstract][Full Text] [Related]
2. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
3. A CDR-grafted (humanized) domain-deleted antitumor antibody.
Slavin-Chiorini DC; Kashmiri SV; Lee HS; Milenic DE; Poole DJ; Bernon E; Schlom J; Hand PH
Cancer Biother Radiopharm; 1997 Oct; 12(5):305-16. PubMed ID: 10851481
[TBL] [Abstract][Full Text] [Related]
4. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts.
Roberson PL; Yokoyama S; Rogers BE; Buchsbaum DJ
Cancer Biother Radiopharm; 2003 Apr; 18(2):239-47. PubMed ID: 12804050
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
[TBL] [Abstract][Full Text] [Related]
8. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
Kashmiri SV; Shu L; Padlan EA; Milenic DE; Schlom J; Hand PH
Hybridoma; 1995 Oct; 14(5):461-73. PubMed ID: 8575795
[TBL] [Abstract][Full Text] [Related]
9. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin.
Domingo RJ; Reilly RM
Nucl Med Commun; 2000 Jan; 21(1):89-96. PubMed ID: 10717908
[TBL] [Abstract][Full Text] [Related]
10. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
[TBL] [Abstract][Full Text] [Related]
11. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu.
Mohsin H; Jia F; Bryan JN; Sivaguru G; Cutler CS; Ketring AR; Miller WH; Simón J; Frank RK; Theodore LJ; Axworthy DB; Jurisson SS; Lewis MR
Bioconjug Chem; 2011 Dec; 22(12):2444-52. PubMed ID: 22053899
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.
Shen S; Forero A; Meredith RF; LoBuglio AF
Cancer Biother Radiopharm; 2011 Feb; 26(1):127-33. PubMed ID: 21355784
[TBL] [Abstract][Full Text] [Related]
15. Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin.
Koppe MJ; Soede AC; Pels W; Oyen WJ; Goldenberg DM; Bleichrodt RP; Boerman OC
Int J Cancer; 2003 Oct; 106(6):965-72. PubMed ID: 12918078
[TBL] [Abstract][Full Text] [Related]
16. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
Kennel SJ; Brechbiel MW; Milenic DE; Schlom J; Mirzadeh S
Cancer Biother Radiopharm; 2002 Apr; 17(2):219-31. PubMed ID: 12030116
[TBL] [Abstract][Full Text] [Related]
17. A novel monoclonal antibody design for radioimmunotherapy.
Forero A; Meredith RF; Khazaeli MB; Carpenter DM; Shen S; Thornton J; Schlom J; LoBuglio AF
Cancer Biother Radiopharm; 2003 Oct; 18(5):751-9. PubMed ID: 14629823
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
19. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.
Ning S; Trisler K; Wessels BW; Knox SJ
Cancer; 1997 Dec; 80(12 Suppl):2519-28. PubMed ID: 9406705
[TBL] [Abstract][Full Text] [Related]
20. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results.
Zou P; Povoski SP; Hall NC; Carlton MM; Hinkle GH; Xu RX; Mojzisik CM; Johnson MA; Knopp MV; Martin EW; Sun D
World J Surg Oncol; 2010 Aug; 8():65. PubMed ID: 20691066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
